Compare VIOT & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | ASRT |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 76.0M |
| IPO Year | 2018 | 2004 |
| Metric | VIOT | ASRT |
|---|---|---|
| Price | $1.26 | $18.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 291.9K | 71.4K |
| Earning Date | 03-25-2026 | 03-16-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $0.96 | $16.87 |
| P/E Ratio | $3.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $0.51 |
| 52 Week High | $4.33 | $16.49 |
| Indicator | VIOT | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 87.10 |
| Support Level | $1.22 | $0.69 |
| Resistance Level | $1.50 | N/A |
| Average True Range (ATR) | 0.09 | 0.95 |
| MACD | -0.00 | 0.56 |
| Stochastic Oscillator | 33.33 | 98.48 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.